New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...
A research team led by Prof. JIANG Yanyi from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, ...
The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...
Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun ...
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
GlobalData on MSN5d
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancerThe US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
Adenocarcinoma grows in the tissue of the prostate gland, but other types of cancer can also start in the prostate or spread ...
59mon MSN
This is also Sun Pharma's second acquisition in less than three months and comes as the company looks to size up its specialty therapy portfolio.
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback